ImmunityBio (IBRX)
(Delayed Data from NSDQ)
$5.79 USD
-0.19 (-3.18%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $5.80 +0.01 (0.17%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth C Momentum F VGM
Price, Consensus and EPS Surprise
IBRX 5.79 -0.19(-3.18%)
Will IBRX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for IBRX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for IBRX
ImmunityBio (IBRX) Gains 17% in the Past Week: Here's Why
Here's Why ImmunityBio (IBRX) Is a Great 'Buy the Bottom' Stock Now
IBRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
ImmunityBio (IBRX)'s Technical Outlook is Bright After Key Golden Cross
Qiagen (QGEN) Q3 Earnings and Revenues Surpass Estimates
Should IQ Chaikin U.S. Small Cap ETF (CSML) Be on Your Investing Radar?
Other News for IBRX
3 Top Cancer Treatment Stocks to Buy Now
Largest borrow rate increases among liquid names
ImmunityBio: Positive Near-Term Catalysts Create Strong Short Squeeze Potential
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
ImmunityBio spikes after commercial update on lead drug Anktiva